AU3827699A - Use of interleukin-18 as vaccine adjuvant - Google Patents
Use of interleukin-18 as vaccine adjuvant Download PDFInfo
- Publication number
- AU3827699A AU3827699A AU38276/99A AU3827699A AU3827699A AU 3827699 A AU3827699 A AU 3827699A AU 38276/99 A AU38276/99 A AU 38276/99A AU 3827699 A AU3827699 A AU 3827699A AU 3827699 A AU3827699 A AU 3827699A
- Authority
- AU
- Australia
- Prior art keywords
- canine
- equine
- vaccine
- seq
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003810 Interleukin-18 Human genes 0.000 title claims description 69
- 108090000171 Interleukin-18 Proteins 0.000 title claims description 69
- 239000012646 vaccine adjuvant Substances 0.000 title claims description 4
- 229940124931 vaccine adjuvant Drugs 0.000 title claims description 4
- 241000282465 Canis Species 0.000 claims description 27
- 241000283073 Equus caballus Species 0.000 claims description 26
- 229960005486 vaccine Drugs 0.000 claims description 26
- 239000002671 adjuvant Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 4
- 108010041986 DNA Vaccines Proteins 0.000 claims description 3
- 229940021995 DNA vaccine Drugs 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 24
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 244000052769 pathogen Species 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 230000001717 pathogenic effect Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 12
- 239000013543 active substance Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960000814 tetanus toxoid Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 159000000013 aluminium salts Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- KRZWEBVPFGCYMY-UHFFFAOYSA-M methylmercury(1+);hydroxide Chemical compound [OH-].[Hg+]C KRZWEBVPFGCYMY-UHFFFAOYSA-M 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- -1 -propiolactone Chemical compound 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000960947 Rattus norvegicus Interleukin-18 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000003804 extraction from natural source Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 102000043959 human IL18 Human genes 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000003751 purification from natural source Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98201451 | 1998-05-07 | ||
EP98201451 | 1998-05-07 | ||
PCT/EP1999/003098 WO1999056775A1 (en) | 1998-05-07 | 1999-05-04 | Use of interleukin-18 as vaccine adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3827699A true AU3827699A (en) | 1999-11-23 |
Family
ID=8233676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU38276/99A Abandoned AU3827699A (en) | 1998-05-07 | 1999-05-04 | Use of interleukin-18 as vaccine adjuvant |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1075275A1 (ja) |
JP (1) | JP2002513547A (ja) |
AU (1) | AU3827699A (ja) |
CA (1) | CA2328059A1 (ja) |
WO (1) | WO1999056775A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999007851A1 (en) * | 1997-08-07 | 1999-02-18 | Toray Industries, Inc. | CANINE INTERLEUKIN 18, CANINE INTERLEUKIN 1β CONVERTASE, DNA SEQUENCES ENCODING THE SAME, PROCESS FOR PRODUCING INTERLE UKIN 18, AND REMEDIES FOR CANINE IMMUNOLOGICAL DISEASES |
US6818444B2 (en) * | 2000-08-04 | 2004-11-16 | Heska Corporation | Canine and feline proteins, nucleic acid molecules and uses thereof |
GB0323968D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
GB2414775B (en) | 2004-05-28 | 2008-05-21 | Cilag Ag Int | Releasable coupling and injection device |
GB2414400B (en) | 2004-05-28 | 2009-01-14 | Cilag Ag Int | Injection device |
GB2414402B (en) | 2004-05-28 | 2009-04-22 | Cilag Ag Int | Injection device |
GB2424836B (en) | 2005-04-06 | 2010-09-22 | Cilag Ag Int | Injection device (bayonet cap removal) |
GB2425062B (en) | 2005-04-06 | 2010-07-21 | Cilag Ag Int | Injection device |
US20110098656A1 (en) | 2005-09-27 | 2011-04-28 | Burnell Rosie L | Auto-injection device with needle protecting cap having outer and inner sleeves |
GB2438591B (en) | 2006-06-01 | 2011-07-13 | Cilag Gmbh Int | Injection device |
SE532249C2 (sv) * | 2006-11-13 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering |
GB2461085B (en) | 2008-06-19 | 2012-08-29 | Cilag Gmbh Int | Injection device |
GB2515032A (en) | 2013-06-11 | 2014-12-17 | Cilag Gmbh Int | Guide for an injection device |
GB2515039B (en) | 2013-06-11 | 2015-05-27 | Cilag Gmbh Int | Injection Device |
GB2517896B (en) | 2013-06-11 | 2015-07-08 | Cilag Gmbh Int | Injection device |
GB2515038A (en) | 2013-06-11 | 2014-12-17 | Cilag Gmbh Int | Injection device |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010072A1 (en) * | 1996-09-09 | 1998-03-12 | Cornell Research Foundation, Inc. | INTERFERON-η INDUCING FACTOR IN NEUROENDOCRINE CELLS |
CA2745736C (en) * | 1996-10-23 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
WO1999007851A1 (en) * | 1997-08-07 | 1999-02-18 | Toray Industries, Inc. | CANINE INTERLEUKIN 18, CANINE INTERLEUKIN 1β CONVERTASE, DNA SEQUENCES ENCODING THE SAME, PROCESS FOR PRODUCING INTERLE UKIN 18, AND REMEDIES FOR CANINE IMMUNOLOGICAL DISEASES |
-
1999
- 1999-05-04 JP JP2000546799A patent/JP2002513547A/ja not_active Withdrawn
- 1999-05-04 WO PCT/EP1999/003098 patent/WO1999056775A1/en not_active Application Discontinuation
- 1999-05-04 AU AU38276/99A patent/AU3827699A/en not_active Abandoned
- 1999-05-04 CA CA002328059A patent/CA2328059A1/en not_active Abandoned
- 1999-05-04 EP EP99920854A patent/EP1075275A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1999056775A1 (en) | 1999-11-11 |
JP2002513547A (ja) | 2002-05-14 |
CA2328059A1 (en) | 1999-11-11 |
EP1075275A1 (en) | 2001-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3827699A (en) | Use of interleukin-18 as vaccine adjuvant | |
US8114409B2 (en) | Structural proteins of fish pancreatic disease virus and uses thereof | |
US6204250B1 (en) | Immunization of infants | |
WO1998022145A9 (en) | Immunization of infants | |
US7645455B2 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
EP0510773B1 (en) | Canine coronavirus subunit vaccine | |
WO2005021029A2 (en) | Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris) | |
CA2086739A1 (en) | Ehv-4 glycoprotein vaccine | |
US20040229827A1 (en) | Dna immunization vectors | |
EP0614979A1 (en) | Hog cholera virus vaccine and diagnostic | |
WO2022003155A1 (en) | A dna plasmid sars-coronavirus-2/covid-19 vaccine | |
CA2464338A1 (en) | Infectious salmon anaemia virus vaccine | |
AU2003249893B2 (en) | Avian cytokines, such IL-12, comprising a p40 and/or p35 Subunit(s) | |
CN117003885A (zh) | H5n8禽流感广谱性疫苗的开发及其应用 | |
CN117229370A (zh) | H5n6禽流感广谱性疫苗的开发及其应用 | |
EP1721982B1 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
EA006743B1 (ru) | Стимуляция тимозином генетической иммунизации | |
Xicheng et al. | Embryo vaccination against eimeria tenella and e. acervulina infections using recombinant proteins and cytokine adjuvants | |
Letvin et al. | Augmentation and Suppression of | |
Ono | Patent Report |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |